邯郸市女性人乳头瘤病毒中和抗体研究  

Prevalence of neutralizing antibodies to HPV among female outpatients in Handan City

作　　者：李玲玉[1] 蒋霏 刘欢 刘树芳 王美玉 黄维金[2] LI Ling-yu;JIANG Fei;LIU Huan;LIU Shu-fang;WANG Mei-yu;HUANG Wei-jin(Department of Dermatology,Affilated Hospital of Hebei Engineering University,Handan 056002,Hebei Province,China;不详)

机构地区：[1]河北工程大学附属医院皮肤科,河北邯郸056002 [2]中国食品药品检定研究院艾滋病性病病毒疫苗室,国家卫生健康委员会生物技术产品检定方法与标准化重点实验,国家药品监督管理局生物制品质量研究与评价重点实验室,北京102629 [3]河北大学公共卫生学院预防医学系,河北保定071002

出　　处：《微生物学免疫学进展》2021年第5期60-66,共7页Progress In Microbiology and Immunology

基　　金：国家科技重大专项“创新生物技术药物评价及标准化关键技术研究”(2018ZX09101-001);高通量人乳头瘤病毒疫苗免疫原性评价技术研究(2019x1)。

摘　　要：目的了解邯郸市女性人群人乳头瘤病毒(human papilloma virus, HPV)中和抗体的研究,为当地制定适当的宫颈癌(uterine cervical carcinoma, UCC)防控策略和HPV疫苗接种提供依据。方法采用横断面的调查方法,以2019年9—12月河北工程大学附属医院就诊未接种过HPV疫苗的女性为调查对象,开展流行病学调查。采集血清样本,假病毒中和试验检测9种HPV基因型的血清中和抗体。结果 216份血清样本检出HPV阳性血清33份,阳性率15.28%。低危型血清13份,阳性率6.02%(95%CI:3.24%~10.07%);高危型血清27份,阳性率为12.50%(95%CI:8.4%~17.66%)。各基因型的中和抗体GMT为120~696。33份HPV阳性血清样本中,单一阳性血清样本22份,单一高危型阳性就有17份,占77.21%;多重阳性血清样本11份,均为多重高危型阳性样本。5个年龄组中,第1、2、3组的女性人群HPV阳性血清随着年龄的增长明显增加,而第4、5组则随着年龄的增长明显下降;第3组HPV检测出阳性血清最多,有12份,阳性率为25.00%;第5组HPV阳性血清检出最少,仅有3份,阳性率为15.00%,年龄组间阳性率差异无统计学意义(χ^(2)=4.957、P=0.292,P>0.05)。乡镇和市区HPV阳性率分别为16.91%、12.50%;单一和多重HPV感染乡镇均高于城区,地区间阳性率差异无统计学意义(χ^(2)=0.757、P=0.384,P>0.05)。中专及高中以上人群HPV阳性率最高,占20.27%,其单一阳性率高于其他人群,不同文化程度人群HPV阳性率差异无统计学意义(χ^(2)=3.152、P=0.207,P>0.05)。结论邯郸市5个未接种过HPV疫苗年龄组均检出HPV抗体,自然感染产生的中和抗体滴度不高,阳性率处于全国较低水平。高危型血清样本阳性率很高,须及时采取主动干预措施,提高人群对HPV感染的认知,并在特定年龄段积极推广HPV多价疫苗的接种和提高接种率。Objective The present study aimed to investigate the prevalence of neutralizing antibodies to human papilloma virus(HPV) among female outpatients in Handan City, to better understand the prevention strategy of uterine cervical carcinoma(UCC) and HPV vaccination. Methods A cross-sectional survey was conducted to investigate the epidemiological characteristics among non-vaccinated female outpatients in the Affiliated Hospital of Hebei Engineering University from September to December 2019, serum samples were collected and pseudovirions neutralization assay was conducted to evaluate neutralizing antibodies against low-risk HPV-6,-11 and high-risk HPV-16,-18,-31,-33,-45,-52 and-58. Results Of the 216 enrolled subjects, 15.28%(33/216) exhibited HPV antibodies. Antibodies against low-risk and high-risk HPV accounted for 6.02%(13/216, 95% CI: 3.24%-10.07%), and 12.50%(27/216, 95% CI: 8.4%-17.66%), respectively. The geometric mean titers(GMT) of neutralizing antibodies against all HPV subtypes ranged from 120 to 696. Among 33 antibody positive samples, 22 samples showed positive to single HPV subtype, while the other 11 samples to multiple subtypes.77.21%(17/22) of single positive and 100%(11/11) of multiple positive samples were against high-risk HPV subtypes. Neutralizing antibodies against HPV were detected in 15.00%(3/20) and 25.00%(12/48) at the fifth(65-89 years old) and third(30-45 years old) group, respectively. HPV positive rate increased in the first three groups, while decreased in the last two groups. However, statistical analysis indicated no difference among different groups(χ^(2)=4.957, P=0.292, P>0.05). The HPV positive rates in towns and urban areas were 16.91% and 12.50%, respectively.Although single and multiple HPV subtypes in towns were much higher, there showed no significant difference(χ^(2)=0.757, P=0.384, P>0.05). In addition, subjects with secondary/high school degree or above showed the highest HPV antibody positive rate(20.27%), as well as the highest single HPV subtype positive rate. Howeve

关 键 词：人乳头瘤病毒 宫颈癌 中和抗体 

分 类 号：R737.33[医药卫生—肿瘤]